LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 7, 2006--NitroMed, Inc. (NASDAQ: NTMD) today announced that it will present at the Biotechnology Industry Organization’s annual BIO CEO & Investor Conference, being held February 14-15 at the Waldorf=Astoria hotel in New York. Michael D. Loberg, Ph.D., NitroMed’s President and Chief Executive Officer, will present a corporate overview and progress report on the commercial launch of BiDil(R) (isosorbide dinitrate/hydralazine hydrochloride) on Tuesday, February 14, at 11:00 am (ET).
